美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

OPUS GENETICS INC

5.57

-0.2500-4.30%

成交量：48.24萬

成交額：271.51萬

市值：4.63億

市盈率：-4.31

高：5.80

開：5.80

低：5.51

收：5.82

52周最高：7.07

52周最低：1.35

股本：8,319.58萬

流通股本：6,445.14萬

量比：0.13

換手率：0.75%

股息：- -

股息率：- -

每股收益(TTM):-1.2925

每股收益(LYR):-0.8000

淨資產收益率：-4796.52%

總資產收益率：-48.06%

市淨率：-35.68

市盈率(LYR):-6.96

資料載入中...

總覽公司新聞資訊公告

健康快訊：試驗性眼藥水緩解了駕駛員的夜視問題

健康快訊：試驗性眼藥水緩解了駕駛員的夜視問題

Opus Genetics因早期至中期眼部疾病基因療法數據向好，股價創下5年新高

Opus Genetics宣佈Opgx-Best1 1/2期臨床試驗低劑量隊列1數據積極，FDA C類會議成功，2027年有望啓動3期給藥

Opus Genetics：Opgx-Best1展現良好安全性，無嚴重不良事件或劑量限制毒性

Opus Genetics 完成 LCA5 相關遺傳性視網膜疾病候選藥物 Opgx-Lca5 註冊性 III 期試驗患者入組

Opus Genetics宣佈與美國食品藥品監督管理局就Opgx-lca5治療Lca5相關遺傳性視網膜疾病的III期註冊試驗設計達成一致

Opus Genetics提交SEC文件：現有股東申請轉售最多268萬股普通股

Opus Genetics宣佈FDA接受Opgx-Lca5納入罕見病證據原則計劃

奧伯蘭資本承諾以每股4.48美元價格向Opus Genetics Inc注資500萬美元

Opus Genetics Inc：奧伯蘭資本可選擇將最多10%票據轉換為公司股票，每股作價6.72美元

Opus Genetics Inc獲得最高1.55億美元非稀釋性融資首期注資3500萬美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IRD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":5.57,"timestamp":1789571513976,"preClose":5.82,"halted":0,"volume":482405,"delay":0,"changeRate":-0.0429553264604811,"floatShares":64451400,"shares":83195823,"eps":-1.292468,"marketStatus":"交易中","change":-0.25,"latestTime":"09-16 11:11:54 EDT","open":5.8,"high":5.8,"low":5.5134,"amount":2715105.4446285,"amplitude":0.049244,"askPrice":5.58,"askSize":205,"bidPrice":5.56,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-1.292468,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":5.82,"preHourTrading":{"tag":"盘前","latestPrice":5.82,"preClose":5.82,"latestTime":"09:29 EDT","volume":1218,"amount":7093.870728,"timestamp":1789565383526,"change":0,"changeRate":0,"amplitude":0.039519},"postHourTrading":{"tag":"盘后","latestPrice":5.7561,"preClose":5.82,"latestTime":"19:49 EDT","volume":10625,"amount":61560.653,"timestamp":1789516168619,"change":-0.0639,"changeRate":-0.010979,"amplitude":0.013746},"volumeRatio":0.131637,"impliedVol":1.2209,"impliedVolPercentile":0.3307},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":64451400,"roa":"-48.06%","roe":"-4796.52%","lyrEps":-0.8,"volumeRatio":0.131637,"shares":83195823,"dividePrice":0,"high":5.8,"amplitude":0.049244,"preClose":5.82,"low":5.5134,"week52Low":1.35,"pbRate":"-35.68","psRate":"47.02","week52High":7.07,"institutionHeld":0,"latestPrice":5.57,"committee":0.322314,"eps":-1.292468,"divideRate":0,"volume":482405,"delay":0,"ttmEps":-1.292468,"open":5.8,"prevYearClose":2.01,"prevWeekClose":6.04,"prevMonthClose":3.62,"prevQuarterClose":4.11,"fiveDayClose":5.73,"twentyDayClose":3.69,"sixtyDayClose":4.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"IRD","fiscalQuarterEnding":"2026/06","expectedEps":-0.15,"name":null,"time":"盤前","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2026-05-12","symbol":"IRD","fiscalQuarterEnding":"2026/03","expectedEps":-0.16,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2026-03-10","symbol":"IRD","fiscalQuarterEnding":"2025/12","expectedEps":-0.11,"name":null,"time":"盤前","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-11-12","symbol":"IRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.14,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2025-08-13","symbol":"IRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.25,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2778,"buy":0.7222,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7222,"analysts":18,"updateTime":1785384000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2026-09-15","current":-4.309584,"percent":0.106838,"low":-8.249622,"twenty":-3.085863,"median":-2.022322,"eighty":-1.134766,"high":-0.560128,"avg":-2.412671,"sd":1.787581,"marketCap":496679063},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197},{"date":"2025-07-11","current":-1.139893,"twenty":-1.351342,"median":-1.160017,"eighty":-0.782117,"marketCap":66820540},{"date":"2025-07-18","current":-1.185692,"twenty":-1.346698,"median":-1.152239,"eighty":-0.783669,"marketCap":69505294},{"date":"2025-07-25","current":-1.231492,"twenty":-1.339732,"median":-1.160017,"eighty":-0.783669,"marketCap":72190048},{"date":"2025-08-01","current":-1.129716,"twenty":-1.335088,"median":-1.160248,"eighty":-0.785825,"marketCap":66223928},{"date":"2025-08-08","current":-1.10936,"twenty":-1.335088,"median":-1.151155,"eighty":-0.789762,"marketCap":65030704},{"date":"2025-08-15","current":-1.213067,"twenty":-1.335088,"median":-1.150071,"eighty":-0.791428,"marketCap":70691504},{"date":"2025-08-22","current":-1.177087,"twenty":-1.335088,"median":-1.151155,"eighty":-0.791428,"marketCap":68594722},{"date":"2025-08-29","current":-1.287434,"twenty":-1.335088,"median":-1.160248,"eighty":-0.791428,"marketCap":75025207},{"date":"2025-09-05","current":-1.384803,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"marketCap":80699383},{"date":"2025-09-12","current":-1.525447,"twenty":-1.342054,"median":-1.174821,"eighty":-0.822134,"marketCap":88895414},{"date":"2025-09-19","current":-1.611997,"twenty":-1.365273,"median":-1.182227,"eighty":-0.876364,"marketCap":93939125},{"date":"2025-09-26","current":-1.860829,"twenty":-1.384803,"median":-1.184928,"eighty":-0.929339,"marketCap":108439795},{"date":"2025-10-03","current":-1.947379,"twenty":-1.400101,"median":-1.195775,"eighty":-0.939944,"marketCap":113483507},{"date":"2025-10-10","current":-2.152936,"twenty":-1.42988,"median":-1.207384,"eighty":-0.94314,"marketCap":125462322},{"date":"2025-10-17","current":-2.174573,"twenty":-1.477844,"median":-1.207384,"eighty":-0.951343,"marketCap":126723249},{"date":"2025-10-24","current":-2.163754,"twenty":-1.521119,"median":-1.217191,"eighty":-0.957164,"marketCap":126092786},{"date":"2025-10-31","current":-2.131298,"twenty":-1.627334,"median":-1.225421,"eighty":-0.958345,"marketCap":124201394},{"date":"2025-11-07","current":-2.196211,"twenty":-1.661499,"median":-1.23256,"eighty":-0.960734,"marketCap":127984177},{"date":"2025-11-14","current":-2.001473,"twenty":-1.74585,"median":-1.242213,"eighty":-0.964942,"marketCap":116635827},{"date":"2025-11-21","current":-1.951541,"twenty":-1.828372,"median":-1.253822,"eighty":-0.975077,"marketCap":133100921},{"date":"2025-11-28","current":-2.153773,"twenty":-1.878321,"median":-1.253822,"eighty":-0.98727,"marketCap":146893763},{"date":"2025-12-05","current":-2.254889,"twenty":-1.925381,"median":-1.265432,"eighty":-0.988735,"marketCap":153790183},{"date":"2025-12-12","current":-2.467233,"twenty":-1.950709,"median":-1.277041,"eighty":-0.996674,"marketCap":168272667},{"date":"2025-12-19","current":-2.002099,"twenty":-2.002099,"median":-1.288651,"eighty":-1.007767,"marketCap":136549131},{"date":"2025-12-26","current":-2.062768,"twenty":-2.022322,"median":-1.288651,"eighty":-1.0085,"marketCap":140686984},{"date":"2026-01-02","current":-2.032433,"twenty":-2.02248,"median":-1.288651,"eighty":-1.00907,"marketCap":138618058},{"date":"2026-01-09","current":-2.022322,"twenty":-2.035652,"median":-1.288651,"eighty":-1.009619,"marketCap":137928416},{"date":"2026-01-16","current":-2.103215,"twenty":-2.062768,"median":-1.30026,"eighty":-1.016154,"marketCap":143445552},{"date":"2026-01-23","current":-2.527902,"twenty":-2.079519,"median":-1.303662,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-01-30","current":-2.527902,"twenty":-2.105793,"median":-1.31187,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-02-06","current":-2.608795,"twenty":-2.126582,"median":-1.317674,"eighty":-1.019861,"marketCap":177927656},{"date":"2026-02-13","current":-3.427836,"twenty":-2.136977,"median":-1.323479,"eighty":-1.031375,"marketCap":233788665},{"date":"2026-02-20","current":-3.609844,"twenty":-2.149226,"median":-1.323479,"eighty":-1.038117,"marketCap":246202222},{"date":"2026-02-27","current":-3.630068,"twenty":-2.153773,"median":-1.330709,"eighty":-1.044184,"marketCap":247581506},{"date":"2026-03-06","current":-4.823238,"twenty":-2.163754,"median":-1.335088,"eighty":-1.055298,"marketCap":328959272},{"date":"2026-03-13","current":-6.821589,"twenty":-2.163832,"median":-1.335088,"eighty":-1.05838,"marketCap":338289413},{"date":"2026-03-20","current":-6.571003,"twenty":-2.174573,"median":-1.340893,"eighty":-1.062543,"marketCap":325862626},{"date":"2026-03-27","current":-6.48492,"twenty":-2.196211,"median":-1.358307,"eighty":-1.072721,"marketCap":321593683},{"date":"2026-04-02","current":-6.728822,"twenty":-2.279157,"median":-1.369917,"eighty":-1.078827,"marketCap":333689021},{"date":"2026-04-10","current":-7.890943,"twenty":-2.31549,"median":-1.383164,"eighty":-1.078974,"marketCap":391319747},{"date":"2026-04-17","current":-8.249622,"twenty":-2.347317,"median":-1.393136,"eighty":-1.079587,"marketCap":409107008},{"date":"2026-04-24","current":-7.474875,"twenty":-2.424764,"median":-1.39894,"eighty":-1.079843,"marketCap":370686524},{"date":"2026-05-01","current":-7.357517,"twenty":-2.49456,"median":-1.404745,"eighty":-1.081468,"marketCap":364866631},{"date":"2026-05-08","current":-7.717474,"twenty":-2.527902,"median":-1.450845,"eighty":-1.086096,"marketCap":382717249},{"date":"2026-05-15","current":-3.318654,"twenty":-2.605325,"median":-1.471353,"eighty":-1.089005,"marketCap":354870285},{"date":"2026-05-22","current":-2.864592,"twenty":-2.625631,"median":-1.50381,"eighty":-1.089833,"marketCap":306316604},{"date":"2026-05-29","current":-2.804496,"twenty":-2.764432,"median":-1.520037,"eighty":-1.093147,"marketCap":299890382},{"date":"2026-06-05","current":-3.098301,"twenty":-2.804496,"median":-1.567278,"eighty":-1.099183,"marketCap":331307470},{"date":"2026-06-12","current":-2.976252,"twenty":-2.841362,"median":-1.641006,"eighty":-1.10936,"marketCap":318256557},{"date":"2026-06-18","current":-3.09043,"twenty":-2.862186,"median":-1.648544,"eighty":-1.10936,"marketCap":330465888},{"date":"2026-06-26","current":-2.831626,"twenty":-2.921273,"median":-1.671763,"eighty":-1.117502,"marketCap":302791405},{"date":"2026-07-02","current":-3.181773,"twenty":-2.964753,"median":-1.703207,"eighty":-1.119538,"marketCap":340233353},{"date":"2026-07-10","current":-3.103979,"twenty":-3.005472,"median":-1.779688,"eighty":-1.123486,"marketCap":331914656},{"date":"2026-07-17","current":-2.5326,"twenty":-2.998741,"median":-1.85001,"eighty":-1.127372,"marketCap":270815938},{"date":"2026-07-24","current":-2.254631,"twenty":-2.977774,"median":-1.874663,"eighty":-1.129113,"marketCap":241092238},{"date":"2026-07-31","current":-2.964995,"twenty":-2.973207,"median":-1.900983,"eighty":-1.129716,"marketCap":317052806},{"date":"2026-08-07","current":-2.854241,"twenty":-2.967182,"median":-1.931317,"eighty":-1.129716,"marketCap":307144906},{"date":"2026-08-14","current":-2.87602,"twenty":-2.967182,"median":-1.947379,"eighty":-1.129716,"marketCap":309488461},{"date":"2026-08-21","current":-3.185269,"twenty":-2.973207,"median":-1.951541,"eighty":-1.129716,"marketCap":342766790},{"date":"2026-08-28","current":-2.976526,"twenty":-2.991855,"median":-1.986619,"eighty":-1.13016,"marketCap":320303918},{"date":"2026-09-04","current":-3.556368,"twenty":-3.015947,"median":-2.002099,"eighty":-1.13167,"marketCap":382700785},{"date":"2026-09-11","current":-4.69286,"twenty":-3.069117,"median":-2.01221,"eighty":-1.133546,"marketCap":504998645},{"date":"2026-09-15","current":-4.615547,"twenty":-3.085863,"median":-2.022322,"eighty":-1.134766,"marketCap":496679063}],"updateTime":1789568369793},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666488518","title":"健康快訊：試驗性眼藥水緩解了駕駛員的夜視問題","url":"https://stock-news.laohu8.com/highlight/detail?id=2666488518","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666488518?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 03:21","pubTimestamp":1789068080,"startTime":"0","endTime":"0","summary":"健康快讯：试验性眼药水缓解了驾驶员的夜视问题《Health Rounds》荣获2026年出版商通讯奖“最佳科学通讯”奖，每周二和周四发布。到第15天，21%的用药组受试者出现了此类改善，而安慰剂组的比例仍维持在3%，未发生变化。到第15天，使用Opus Genetics眼药水的患者报告的眩光、光晕和星芒现象也显著少于安慰剂组患者。该公司还宣布，该眼药水的第二项III期临床试验取得了令人鼓舞的初步结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nL4T4521IY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666181075","title":"健康快訊：試驗性眼藥水緩解了駕駛員的夜視問題","url":"https://stock-news.laohu8.com/highlight/detail?id=2666181075","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666181075?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 03:21","pubTimestamp":1789068080,"startTime":"0","endTime":"0","summary":"健康快讯：试验性眼药水缓解了驾驶员的夜视问题《Health Rounds》荣获2026年出版商通讯奖“最佳科学通讯”奖，每周二和周四发布。到第15天，21%的用药组受试者出现了此类改善，而安慰剂组的比例仍维持在3%，未发生变化。到第15天，使用Opus Genetics眼药水的患者报告的眩光、光晕和星芒现象也显著少于安慰剂组患者。该公司还宣布，该眼药水的第二项III期临床试验取得了令人鼓舞的初步结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nL4S4521IY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666362035","title":"Opus Genetics因早期至中期眼部疾病基因療法數據向好，股價創下5年新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2666362035","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666362035?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 22:04","pubTimestamp":1788962661,"startTime":"0","endTime":"0","summary":"BUZZ-Opus Genetics因早期至中期眼部疾病基因疗法数据向好，股价创下5年新高9月9日-** 生物技术公司Opus Genetics（IRD.O）股价上涨55.3%，至6.75美元——创下2021年3月以来的最高水平** 该公司表示，其用于治疗BEST1相关视网膜疾病的实验性基因疗法OPGx-BEST1（该类罕见遗传性眼疾会导致视力进行性丧失乃至失明），在一项早期至中期临床研究中，接受","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4S4511AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103565944","title":"Opus Genetics宣佈Opgx-Best1 1/2期臨床試驗低劑量隊列1數據積極，FDA C類會議成功，2027年有望啓動3期給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1103565944","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103565944?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:02","pubTimestamp":1788951771,"startTime":"0","endTime":"0","summary":"Opus Genetics今日重磅披露——其核心在研疗法Opgx-Best1在1/2期临床试验低剂量队列1中斩获积极数据，这一里程碑式的进展为后续开发铺平了道路。与此同时，公司与美国食品药品监督管理局召开的C类会议也以圆满收官告捷。种种迹象表明，该项目若顺利推进，2027年或将迎来关键的3期临床给药阶段。更值得关注的是，FDA的C类会议反馈为产品的监管路径提供了清晰指引——双方就后续开发策略达成共识，扫清了研发征途上的重要障碍。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166032906","title":"Opus Genetics：Opgx-Best1展現良好安全性，無嚴重不良事件或劑量限制毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1166032906","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166032906?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:01","pubTimestamp":1788951701,"startTime":"0","endTime":"0","summary":"Opus Genetics宣布，其候选药物Opgx-Best1在临床研究中呈现出令人鼓舞的安全性特征——未观察到任何严重不良事件，也未出现剂量限制性毒性反应。Opgx-Best1作为一种在研疗法，其安全性数据的公布，是药物开发进程中的一个关键里程碑。这意味着，Opgx-Best1有望为患者提供一种更为安全可靠的治疗选项。基于目前的数据，Opgx-Best1似乎已经顺利跨越了这一前置门槛。这一进展不仅对Opus Genetics公司意义重大，对相关疾病领域的患者而言，也意味着新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133103691","title":"Opus Genetics 完成 LCA5 相關遺傳性視網膜疾病候選藥物 Opgx-Lca5 註冊性 III 期試驗患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=1133103691","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133103691?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 19:02","pubTimestamp":1785754942,"startTime":"0","endTime":"0","summary":"Opus Genetics 宣布，为其针对 LCA5 相关遗传性视网膜疾病研发的候选药物 Opgx-Lca5，已成功完成注册性 III 期临床试验的患者入组工作。这一里程碑，标志着该药物研发进程迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198935656","title":"Opus Genetics宣佈與美國食品藥品監督管理局就Opgx-lca5治療Lca5相關遺傳性視網膜疾病的III期註冊試驗設計達成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1198935656","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198935656?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 19:03","pubTimestamp":1783335801,"startTime":"0","endTime":"0","summary":"Opus Genetics公司宣布，已与美国食品药品监督管理局就Opgx-lca5针对Lca5相关遗传性视网膜疾病的III期注册试验设计达成共识。这一关键进展标志着该候选疗法的临床开发路径进一步明确，为其后续的注册申请奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106560473","title":"Opus Genetics提交SEC文件：現有股東申請轉售最多268萬股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1106560473","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106560473?lang=zh_tw&edition=fundamental","pubTime":"2026-06-06 04:34","pubTimestamp":1780691651,"startTime":"0","endTime":"0","summary":"Opus Genetics已向美国证券交易委员会提交文件，申请由现有股东转售最多268万股公司普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128138132","title":"Opus Genetics宣佈FDA接受Opgx-Lca5納入罕見病證據原則計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1128138132","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128138132?lang=zh_tw&edition=fundamental","pubTime":"2026-05-05 04:32","pubTimestamp":1777926769,"startTime":"0","endTime":"0","summary":"Opus Genetics公司近日宣布，其基因治疗候选药物Opgx-Lca5已获得美国食品药品监督管理局批准，正式纳入罕见病证据原则计划。这一重要进展标志着该公司在针对罕见遗传性视网膜疾病治疗领域的研发迈出关键一步。Opgx-Lca5作为针对LCA5基因突变相关莱伯先天性黑蒙症的治疗方案，此次入选将进一步推动该药物的临床开发进程。对于Opus Genetics而言，此次FDA的认可不仅验证了其科学平台的技术潜力，也为后续与其他监管机构的沟通奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130712669","title":"奧伯蘭資本承諾以每股4.48美元價格向Opus Genetics Inc注資500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130712669","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130712669?lang=zh_tw&edition=fundamental","pubTime":"2026-04-06 19:06","pubTimestamp":1775473583,"startTime":"0","endTime":"0","summary":"奥伯兰资本已正式承诺，将以每股4.48美元的价格对Opus Genetics Inc进行500万美元的股权投资。这项投资将直接用于认购该公司的股票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168121332","title":"Opus Genetics Inc：奧伯蘭資本可選擇將最多10%票據轉換為公司股票，每股作價6.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168121332","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168121332?lang=zh_tw&edition=fundamental","pubTime":"2026-04-06 19:06","pubTimestamp":1775473582,"startTime":"0","endTime":"0","summary":"生物技术公司Opus Genetics Inc宣布，其发行的票据中最多10%的部分，可由投资机构奥伯兰资本（Oberland Capital）自主选择转换为公司普通股，转换价格设定为每股6.72美元。此项条款为奥伯兰资本提供了将债权转换为股权的灵活性，潜在增加了其对公司的持股比例。转换价格的设定也反映了市场对公司股权价值的当前评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169713083","title":"Opus Genetics Inc獲得最高1.55億美元非稀釋性融資 首期注資3500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169713083","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169713083?lang=zh_tw&edition=fundamental","pubTime":"2026-04-06 19:04","pubTimestamp":1775473459,"startTime":"0","endTime":"0","summary":"生物技术公司Opus Genetics Inc近日宣布成功设立新的票据融资机制，通过该渠道可获得总额高达1.55亿美元的非稀释性资金支持。值得关注的是，该融资方案首期即提供3500万美元的即时资金注入。\n此次融资安排采用票据融资模式，既保障了公司研发资金的持续供给，又有效避免了股权稀释对现有股东权益的影响。非稀释性融资的特性使公司在保持资本结构稳定的同时，能够灵活调配资源推进基因治疗领域的创新研究。\n该融资机制将分阶段释放资金，后续款项的拨付将与公司达成特定研发里程碑挂钩。这种结构化设计既体现了投资方对Opus Genetics技术实力的认可，也为公司未来的科研进展提供了持续动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}